ATI Medical Appoints Dr. Michael L. Steinberg to its Scientific Advisory Board.

Business Editors and Health/Medical Writers

BIOWIRE2K

ATI Medical Inc., developer of promising treatments for localized cancer, today announced the appointment of Dr. Michael L. Steinberg, F.A.C.R., to its Scientific Advisory Board.

Dr. Steinberg is a board-certified specialist in radiation oncology. He is a founding partner of the Santa Monica Cancer Treatment Center and Cancer Care Consultants Medical Associates. He is a Clinical Professor at the UCLA School of Medicine.

Dr. Steinberg earned his M.D. degree at the University of Southern California, and completed specialty training in Radiation Oncology at UCLA. In addition, he is past president of the California Radiation Oncology Society and is a Councilor to the American College of Radiology. Dr. Steinberg is chairman of the Cancer Program at Santa Monica/UCLA Medical Center, and is a member of the Physician Advisory Board for the Wellness Community in Santa Monica, Calif. Dr. Steinberg specializes in prostate, head, neck, gynecological, and breast cancers.

In addition to an active clinical practice, Dr. Steinberg currently conducts health services quality research at the RAND Corporation in Santa Monica, and was one of the authors of "Prostate Cancer Patient Outcomes and Choice of Providers: Development of an Infrastructure for Quality Assessment." He is also a member of Medicare's California Carrier Advisory Committee, representing radiation oncology.

In recognition of his contribution and professional leadership in the field of radiation oncology, Dr. Steinberg was elected Fellow of the American College of Radiology. Dr. Steinberg is a Chancellor of the American College of Radiation Oncology and is Chair of the Clinical Practice Committee of the American Society of Therapeutic Radiology and Oncology. In recognition of his superior medical skills, Dr. Steinberg was selected by his peers to be included in Best Doctors in America.

"We are pleased that Dr. Steinberg has joined our Scientific Advisory Board," said W. Tate Scott, president and CEO of ATI Medical. "ATI is focusing on cancer therapies that apply heat and/or radiation simultaneously, or separately, to treat solid tumors, yet we previously had only one Radiation Oncologist on our Advisory Board. Dr. Steinberg brings over 20 years of clinical experience in radiation oncology to ATI, and is a highly recognized leader in the field. We are honored that he has agreed to join our growing Advisory Board."

"I am very interested in the products being developed by ATI Medical," said Dr. Steinberg. "The company's thermal brachytherapy implants represent real breakthrough technology. One of their first products is intended to deliver a standard therapeutic dose of radiation, but can then be heated to thermally ablate tissue, if the cancer recurs locally. Having a built-in second line therapy is very appealing. Another product is being developed to deliver radiation plus hyperthermia simultaneously. Radiation oncologists have wanted to deliver this combination therapy for years, but lacked the technology to do so in a controlled, consistent manner. Elevating tissue temperature increases cell sensitivity to radiation, potentially allowing for a reduction of radiation dose and its side effects."

Prostate cancer is the second leading cause of cancer death in men. The American Cancer Society estimates that, in 2002 in the U.S., 189,000 new cases will be diagnosed, and over 30,000 men will die of the disease.

ATI Medical is a privately held company that is focused on the development and commercialization of a family of implants for the treatment of prostate cancer and other diseases. These products, which are still under development, are intended to apply heat and/or radiation simultaneously or separately to treat solid tumors.

Visit ATI Medical on the Web at atimedical.com.